Why Tempus AI, Inc. (TEM) Stock Rose 10.6% on Aug 21, 2026
The clearest new catalyst: Merck-Moderna Phase 3 validation.
Why did TEM stock rise?
Tempus AI surged 10.6% on August 21, 2026, driven by positive Phase 3 cancer vaccine trial results from Merck and Moderna that validated the genomic-sequencing and oncology data space, a BTIG analyst price-target upgrade to $80, and continued investor enthusiasm around the pending $1.5 billion all-stock acquisition of Personalis. The move also reflected strong Q2 fundamentals, including the company's first quarterly net profit and raised full-year revenue guidance to approximately $1.6 billion.
- Merck-Moderna Phase 3 validation: Positive Phase 3 results for a custom mRNA neoantigen cancer therapy validated the genomic-sequencing and oncology data space in which Tempus operates, providing external validation of the sector's therapeutic potential.
- BTIG analyst upgrade: BTIG raised its price target on TEM from $70 to $80, reinforcing bullish sentiment among growth traders.
- Personalis acquisition momentum: Investor enthusiasm continued building around Tempus AI's planned $1.5 billion all-stock acquisition of Personalis, which expands the company's genomic testing and minimal residual disease (MRD) capabilities.
- Strong Q2 earnings and guidance raise: The company reported its first-ever quarterly net profit and raised full-year revenue guidance to approximately $1.6 billion, demonstrating improved gross margins and operational momentum.
Initial detection
BestStocks first flagged TEM intraday on Aug 21, 2026; this analysis was finalized after the close using the confirmed +10.6% session move and additional catalyst research.
Show the initial intraday note
Tempus AI, Inc. (TEM) moved +10.57% on 2026-08-21, driven by positive analyst sentiment, strong Q2 results, and strategic momentum. The company reported improved gross margins, raised full-year guidance, and achieved its first quarterly net profit. Analyst upgrades from firms including BTIG boosted confidence, while the pending acquisition of Personalis to expand into the molecular residual disease market added to investor optimism.
What to watch next: TEM earnings scheduled for 2026-11-03 (date not yet confirmed), with consensus EPS estimate of −$0.07.
Frequently asked questions
Why did Tempus AI, Inc. (TEM) stock rise on Aug 21, 2026?
Tempus AI surged 10.6% on August 21, 2026, driven by positive Phase 3 cancer vaccine trial results from Merck and Moderna that validated the genomic-sequencing and oncology data space, a BTIG analyst price-target upgrade to $80, and continued investor enthusiasm around the pending $1.5 billion all-stock acquisition of Personalis. The move also reflected strong Q2 fundamentals, including the company's first quarterly net profit and raised full-year revenue guidance to approximately $1.6 billion.
How much did TEM stock rise on Aug 21, 2026?
TEM rose 10.6% during the Aug 21, 2026 trading session.
What were the main drivers behind TEM's move?
Merck-Moderna Phase 3 validation; BTIG analyst upgrade; Personalis acquisition momentum; Strong Q2 earnings and guidance raise.